Ecraid Joins the BEAM Alliance
Ecraid Joins the BEAM Alliance: Strengthening the Clinical Bridge for AMR Innovation
Ecraid is proud to announce its official membership in the BEAM Alliance. This strategic move aligns our pan-European clinical research infrastructure with a powerful community dedicated to tackling antimicrobial resistance (AMR).
The BEAM Alliance brings together companies and stakeholders across Europe and beyond to promote the development of new preventative, diagnostic and therapeutic solutions to tackle AMR, while advocating for policies that support innovation in this field.
Connecting Innovation with an Established Network
As a not-for-profit foundation, part of Ecraid’s mission is to accelerate the development of therapies and diagnostics by providing the necessary clinical research framework. By joining the BEAM Alliance, we are positioning ourselves as the clinical bridge for innovators who need high-quality evidence to bring their solutions to market. This membership creates a direct pipeline between Europe’s most innovative SMEs and Ecraid’s established hospital networks, regulatory expertise, and key opinion leaders.
Key Strategic Benefits
Through this membership, Ecraid will leverage several high-value benefits to support the wider AMR ecosystem:
- Policy and advocacy: We will contribute to shaping the European policy landscape, ensuring that clinical research perspectives are integrated into discussions on PUSH and PULL incentives and regulatory pathways.
- Networking and knowledge exchange: Ecraid gains direct access to a directory of AMR innovators, fostering opportunities for collaborative research at key industry events, including the annual AMR Conference in Basel, Switzerland.
- Monitoring and analysis: We will benefit from BEAM’s specialised monitoring of EU and Member State legislation, better informing our strategic decision-making and the advice we provide to our partners.
- Visibility: Our participation ensures that Ecraid’s network and expertise are visible to the developers who need them most, helping to move novel antimicrobials from the bench to the bedside.
A Coordinated European Response
The mission of this collaboration is clear: to address one of the most pressing global health challenges through cross-sector cooperation.
By working alongside the BEAM Alliance and its members, Ecraid continues to drive forward innovation and strengthen the clinical research capacity required for a more effective European response to antimicrobial resistance.